You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

XALATAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Xalatan, and what generic alternatives are available?

Xalatan is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in XALATAN is latanoprost. There are twenty drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Xalatan

A generic version of XALATAN was approved as latanoprost by AMRING PHARMS on March 22nd, 2011.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for XALATAN?
  • What are the global sales for XALATAN?
  • What is Average Wholesale Price for XALATAN?
Summary for XALATAN
Drug patent expirations by year for XALATAN
Drug Prices for XALATAN

See drug prices for XALATAN

Drug Sales Revenue Trends for XALATAN

See drug sales revenues for XALATAN

Recent Clinical Trials for XALATAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rigshospitalet, DenmarkPhase 4
Icahn School of Medicine at Mount SinaiPhase 4
Samil Pharmaceutical Co., Ltd.Phase 4

See all XALATAN clinical trials

US Patents and Regulatory Information for XALATAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 AT RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for XALATAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ⤷  Sign Up ⤷  Sign Up
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ⤷  Sign Up ⤷  Sign Up
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ⤷  Sign Up ⤷  Sign Up
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ⤷  Sign Up ⤷  Sign Up
Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for XALATAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3461484 21C1024 France ⤷  Sign Up PRODUCT NAME: ASSOCIATION DE NETARSUDIL OU L'UN DE SES SELS ET DE LATANOPROST; REGISTRATION NO/DATE: EU/1/20/1502 20210108
3461484 SPC/GB21/033 United Kingdom ⤷  Sign Up PRODUCT NAME: A COMBINATION OF LATANOPROST AND NETARSUDIL; REGISTERED: UK EU/1/20/1502(FOR NI) 20210107; UK PLGB 16053/0034 20210107
1225168 91541 Luxembourg ⤷  Sign Up 91541, EXPIRES: 20110718
0364417 SPC/GB97/014 United Kingdom ⤷  Sign Up PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
3461484 122021000036 Germany ⤷  Sign Up PRODUCT NAME: LATANOPROST, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, UND NETARSUDIL MESYLAT; REGISTRATION NO/DATE: EU/1/20/1502 20210107
3461484 C202130024 Spain ⤷  Sign Up PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.